National nutrivigilance scheme
|
|
- Reynard Shaw
- 6 years ago
- Views:
Transcription
1 National nutrivigilance scheme Review of nutrivigilance in 2016 March 2017 French Agency for Food, Environmental and Occupational Health & Safety, 14 rue Pierre et Marie Curie, Maisons-Alfort Cedex Telephone: + 33 (0) Fax: + 33 (0) ANSES/PR1/9/01-04 [version d]
2 Key words Nutrivigilance, food supplement, novel food, food intended for specific diets, fortified food page 2 / 19 March 2017
3 CONTENTS Introduction... 4 Acronyms and abbreviations... 5 List of tables... 5 List of figures Review of nutrivigilance reports received by ANSES in Number of reports received Admissibility of cases Identity of the reporters Products reported Types of food supplements reported Types of adverse effects Intrinsic causality Severity of the cases Review of opinions published by ANSES Opinion published in Food supplements for athletes Internal requests in progress Food supplements for pregnant women Food supplements containing spirulina Food supplements containing melatonin Food supplements containing glucosamine and/or chondroitin Review of information and communication actions International exchanges Training activities organised Other actions Conclusions page 3 / 19 March 2017
4 Introduction Implementation of the national nutrivigilance scheme was entrusted to ANSES in July 2009 under the French Act on Regional Health Governance (HPST). The purpose of this scheme is to improve consumer safety by rapidly identifying any possible adverse effects related to the consumption of: - food supplements; - foods or beverages fortified with substances for nutritional or physiological purposes (vitamins, minerals, amino acids, plant extracts, etc.) such as energy drinks; - novel foods and novel ingredients such as phytosterols, guar gum, noni juice; - products intended as food for specific categories of the population (infants, athletes, patients suffering from food allergies, etc.). Healthcare professionals (doctors, pharmacists, dieticians, etc.) are invited to report these specific foods when they identify adverse effects in their patients that they suspect of being related to consumption of these foods. Individuals who wish to submit a report on their own behalf should preferably contact a healthcare professional. The reports are recorded by ANSES while concealing the identity of the consumer, and are then analysed, initially by the Agency (to determine the severity of the incident, the product's composition, the concordance with previous notifications, etc.). For each report, ANSES may contact the reporter again to obtain any missing information if necessary. Reports containing sufficient information are then submitted to medical experts, who analyse the likelihood of a link between consumption of a product and an adverse effect (causality). The Agency informs the authorities of the cases received and may be required to initiate an alert procedure (life-threatening case in which causality is strong). Cases are examined by a group of specialised experts. Depending on the effects observed, the number of cases received and the likelihood of them being associated with consumption of the product in question, the Agency, with the help of the experts, establishes its priorities in terms of risk assessment work to be undertaken. This work leads to the publication of scientific opinions and recommendations intended for healthcare professionals and consumers. These opinions are submitted to the ministries concerned to enable them to implement appropriate management measures. Between the launch of ANSES's nutrivigilance scheme and 31 December 2016, the Agency received 2649 reports of adverse effects. The purpose of this report is to review the activity of the nutrivigilance scheme for page 4 / 19 March 2017
5 Acronyms and abbreviations FISD: Food intended for specific diets ANSM: French Health Products Safety Agency FSNP: Food to which substances are added for nutritional or physiological purposes ("fortified food") FS: Food supplement CAP: French Poison Control Centre CRPV: Regional Pharmacovigilance Centre NF: Novel food List of tables Table 1: Rate of admissibility of cases per reporter type List of figures Figure 1: Change in number of reports between 2009 and Figure 2: Change in the admissibility of cases received since Figure 3: Breakdown of spontaneously reported cases according to their admissibility and reason for nonadmissibility in Figure 4: Identity of reporters (all reports combined)... 9 Figure 5: Identity of the reporters (admissible cases)... 9 Figure 6: Number of admissible cases per reporter type Figure 7: Types of products reported in nutrivigilance (admissible cases) Figure 8: Breakdown of the types of food supplements implicated in the nutrivigilance reports in 2015 and Figure 9: Breakdown of adverse effects reported in 2015 and 2016 (admissible cases) Figure 10: Causality of cases received in 2015 and 2016 (admissible cases) Figure 11: Causality according to the type of effect (admissible cases) Figure 12: Severity of adverse effects reported (admissible cases) Figure 13: Severity according to causality (admissible cases) page 5 / 19 March 2017
6 1 Review of nutrivigilance reports received by ANSES in 2016 Due to the limited number of cases, the quantified data presented below have not undergone comparisons based on statistical tests. 1.1 Number of reports received Figure 1 illustrates the change in the annual number of reports since the creation of the nutrivigilance scheme Figure 1: Change in number of reports between 2009 and 2016 Until 2011, cases of nutrivigilance were spontaneously reported by healthcare professionals. In 2012, ANSES initiated a process of proactively seeking out cases from manufacturers and other vigilance schemes (pharmacovigilance, toxicovigilance). The spontaneous reports were therefore joined by solicited cases. The sharp increase in the number of spontaneous cases in 2013 can be explained by the choice of certain manufacturers, after having been solicited the first time, to spontaneously report other cases brought to their attention. The total number of reports received in 2014 was slightly higher (498 cases) compared to the previous year (474 cases). The number of spontaneously reported cases (183 cases) fell compared to 2013 (343 cases), but was however still in line with the continuous growth observed since 2009, regardless of the 2013 artefact. In addition, until 2014, the ANSM only systematically informed ANSES of serious cases involving a product concerned by nutrivigilance. In 2014, following a request by ANSES to also be notified of non-serious cases, the ANSM transmitted a further 135 cases. In 2015, there was an increase in spontaneous reports but a fall in the number of cases transmitted following solicitation by ANSES, leading to a total number of 432 cases. In 2016 the growth of spontaneous reports was confirmed with an increase of 26 cases over the previous year. However, the decrease in the number of cases transmitted by manufacturers and other vigilance schemes following solicitation by ANSES continued, leading to a total of 340 cases. page 6 / 19 March 2017
7 1.2 Admissibility of cases Analysing admissibility involves verifying that the report received relates to a case that falls within the scope of nutrivigilance, and that it is sufficiently documented to be exploited. This phase may lead ANSES to request additional information from the reporter. From 2009, only sufficiently documented adverse effects occurring under the normal conditions of use of a foodstuff were declared admissible. With effect from 2016, and in accordance with the provisions of the Public Health Code (Art. R1323-3), the adverse effects resulting from a use that is not compliant with normal use (overdoses or suicide attempts) have also been deemed admissible, if they are sufficiently documented. For 2016, one case of overdose and two cases of attempted suicide were thus deemed admissible. Figure 2 illustrates the proportion of admissible cases received since % 73% 16% 27% Figure 2: Change in the admissibility of cases received since 2009 Although the total number of cases decreased between 2015 and 2016, the rate of admissibility increased sharply from 16% to 27%. The proportions of admissible cases and the different reasons for non-admissibility are illustrated by Figure 3. More than half the reported cases (59%) were not admissible because of the absence of sufficient information (product not identified or dates of consumption unknown, for example). page 7 / 19 March 2017
8 Figure 3: Breakdown of spontaneously reported cases according to their admissibility or reason for non-admissibility in 2016 In 2016 there was a decrease in the number of cases compared to the previous year, but an increase in the rate of admissibility. 1.3 Identity of the reporters Accounting for more than 35% of the reports transmitted in 2016, the regional pharmacovigilance centres (CRPV) were the main reporters in nutrivigilance, followed by manufacturers (32.6%). Hospitals accounted for around 10% of reporters, pharmacies 7% and doctors 5%. Individuals, who are not meant to participate directly in the nutrivigilance scheme, reported 4% of cases. Lastly, the Poison Control Centres (CAPs) and the other reporters (nurses, medical testing laboratories, the AGEPS, etc.) each submitted less than 3% of reports (Figure 4). page 8 / 19 March 2017
9 Figure 4: Identity of reporters (all reports combined) If only admissible cases are considered (Figure 5), the notifications from the CRPVs were still the leading source of reports. In contrast, reports from manufacturers represented a smaller proportion. This can be explained by the low rate of admissibility (18%) among these reporters (Figure 6; Table 1). Figure 5: Identity of the reporters (admissible cases) page 9 / 19 March 2017
10 Figure 6: Number of admissible cases per reporter type Table 1: Rate of admissibility of cases per reporter type CRPVs Manufacturers Hospitals Pharmacies Doctors Individuals CAPs Other Admissible cases 31% 18% 34% 43% 28% 14% 33% 33% Non-admissible cases 69% 82% 66% 57% 72% 86% 67% 67% In 2016, the CRPVs were the main reporters in the nutrivigilance scheme, with 121 cases reported, of which 31% were admissible. The remainder of the report only concerns admissible cases, i.e. reports that have been sufficiently documented, involving products falling within the scope of nutrivigilance, used under normal conditions or conditions that are not compliant with normal use (overdoses or suicide attempts). In addition, it should be reiterated that no attempt should be made to interpret the variations observed from one year to the next because of the low number of reported cases. 1.4 Products reported Although nutrivigilance concerns four categories of food products: food supplements (FS), food intended for specific diets (FISD), fortified foods (FSNP), and novel foods (NF), the vast majority of the cases it collects involve food supplements, which accounted for 90.2% of the cases deemed admissible. This predominance of food supplements is seen year after year (Figure 7). page 10 / 19 March 2017
11 Figure 7: Types of products reported in nutrivigilance (admissible cases) 1.5 Types of food supplements reported Among the 92 admissible cases, 83 involved at least one food supplement. The food supplements reported most frequently were those for "Vitality/tone", "Joints" and "Eyesight" (10 cases each). The breakdown, however, shows great variability from one year to the next (Figure 8). page 11 / 19 March 2017
12 Figure 8: Breakdown of the types of food supplements implicated in the nutrivigilance reports in 2015 and Types of adverse effects The main types of adverse effects reported in 2016 involved digestive (25 cases), general (21 cases), liver (15 cases) and dermatological (15 cases) disorders. This breakdown differed from that observed in 2015 (Figure 9), in particular for allergic effects, which decreased sharply. In half of the cases, this decrease was linked to a change in the ranking of allergic effects, which from 2016 were classified with the dermatological effects in the absence of any evidence of an allergic reaction. page 12 / 19 March 2017
13 Figure 9: Breakdown of adverse effects reported in 2015 and 2016 (admissible cases) 1.7 Intrinsic causality For each sufficiently documented report received by the nutrivigilance scheme, the causality is determined, i.e. the likelihood that the adverse effect reported is related to consumption of the product. The method for assessing causality was defined in ANSES's opinion No SA-0195 of 11 May 2011 on the development of a method for determining causality in reports of adverse reactions in nutrivigilance. This opinion is available on the ANSES website. Causality may be: excluded (I0), unlikely (I1), possible (I2), likely (I3) or very likely (I4). Out of the 92 admissible cases whose causality was analysed, causality was excluded in one case (I0), was unlikely (I1) in 18 cases (19.6%), possible (I2) in 38 cases (41.3%), likely (I3) in 31 cases (33.7%) and very likely (I4) in 4 cases (4.3%). This breakdown showed a higher proportion of possible cases than the previous year (Figure 10). page 13 / 19 March 2017
14 Figure 10: Causality of cases received in 2015 and 2016 (admissible cases) Analysing the causality by type of effect reveals that the very likely cases were associated with digestive, cardiovascular, allergic, rheumatologic and other effects. Caution should however be exercised when interpreting this finding, given the low number of cases studied (Figure 11). The sum of the cases presented in this diagram is greater than the number of admissible cases (92) because a single case can report several types of adverse effects. Figure 11: Causality according to the type of effect (admissible cases) page 14 / 19 March 2017
15 1.8 Severity of the cases The scale of severity in nutrivigilance goes from Level 1 (low severity) to Level 4 (death). The admissible effects reported in 2016 were predominantly Level 1 (39%) and 2 (35%) (Figure 12). Figure 12: Severity of adverse effects reported (admissible cases) One single admissible case of Level 4 severity was reported in 2016, concerning liver damage that resulted in the death of the patient. However, the interval between consumption of the product and occurrence of the adverse effect was deemed incompatible, which led to the causality being determined as possible (I2). Figure 13 shows that the cases whose causality was very likely (I4) were of Level 2 or 3 severity, while the cases of likely causality (I3) were predominantly Level 1. Figure 13: Severity according to causality (admissible cases) page 15 / 19 March 2017
16 2 Review of opinions published by ANSES The analysis of reports received by its nutrivigilance scheme enables ANSES, with the help of its experts, to establish its priorities for risk assessment. In this context, since 2009, ANSES has published around a dozen opinions on a wide range of products monitored by nutrivigilance, especially concerning the risks associated with the consumption of certain substances found in food supplements (lutein, zeaxanthin, synephrine, red yeast rice, etc.), so-called energy drinks, and beverages other than breast milk and its substitutes in the diet of infants under one year of age. 2.1 Opinion published in 2016 One opinion was published in 2016 in the framework of an internal request Food supplements for athletes On 7 November 2016, ANSES issued an opinion on the risks associated with the consumption of food supplements for athletes seeking to develop muscle or reduce body fat. Effects that are potentially serious, primarily cardiovascular (tachycardia, arrhythmia and stroke) and psychological (anxiety and mood disorders), have been observed. The Agency therefore advises against the use of these food supplements by people with cardiovascular risk factors or suffering from heart disease, impaired kidney or liver function, or neuropsychiatric disorders, or by children, adolescents, and pregnant or breastfeeding women. ANSES also recommends avoiding the consumption of food supplements containing caffeine before and during any sporting activity, as well as the concomitant consumption of several food supplements, or their combined consumption with medicinal products. ANSES reiterates the need to seek advice from a healthcare professional before taking food supplements. ANSES's opinion can be consulted via the following link: Internal requests in progress Four internal requests are currently being examined. Their publication is planned for Food supplements for pregnant women Fourteen reports of adverse effects that may be associated with the consumption of food supplements during pregnancy have been brought to ANSES's attention since the establishment of the national nutrivigilance scheme. Ten of these reports were ruled admissible. These adverse effects mainly concerned endocrinological and metabolic disorders (neonatal hypercalcaemia and hypothyroidism). As the severity of the effects concerned a vulnerable population (newborns), and the causality was sometimes high, ANSES decided to issue an internal request to assess the endocrine and metabolic risks related to the intake during pregnancy of vitamin D and iodine through food supplements. The results of this expert appraisal will be published in an opinion in the first quarter of Food supplements containing spirulina ANSES issued an internal request to assess the risks associated with the presence of spirulina in food supplements, following the receipt of sixteen reports of adverse effects since the nutrivigilance scheme was set up. Seven of these reports were admissible, and six of these were considered serious according to the definition given by Article R of the Public Health Code. The adverse effects described were mainly allergic, dermatological, digestive and rheumatic. The results of this expert appraisal will be published in an opinion at the start of the second half of page 16 / 19 March 2017
17 2.2.3 Food supplements containing melatonin Since the establishment of the nutrivigilance scheme in 2009, sixty-nine reports of adverse effects likely to be associated with the consumption of food supplements containing melatonin have been brought to the attention of ANSES. The main adverse effects described are general, psychological and cardiovascular. Seven reports had Level 3 severity. Nine reports were comprehensive enough to establish causality, which in six of these was deemed likely. Given the growing renown of this compound and the adverse effects reported, ANSES issued an internal request for an assessment of the risks associated with the consumption of food supplements containing melatonin. The work will lead to an opinion being published in the second half of Food supplements containing glucosamine and/or chondroitin Eighteen reports of adverse effects that may be associated with the consumption of food supplements for joint health containing glucosamine and/or chondroitin have been brought to ANSES's attention since the establishment of the national nutrivigilance scheme. The adverse effects described were mainly dermatological, digestive, haematological and liver effects. Six of these reports were considered admissible, and three of the cases were deemed serious according to the definition given by Article R of the Public Health Code. The causality of one of these serious cases was deemed to be very likely. An ANSES opinion will be published at the end of page 17 / 19 March 2017
18 3 Review of information and communication actions 3.1 International exchanges In the context of the free movement of goods, it is essential to pool knowledge of product composition and the cases reported in other European countries. Apart from France's initiative in terms of nutrivigilance, several other countries are investigating or have already established a similar scheme (Italy, Sweden, etc.). In 2014, in order to bring these schemes together and raise awareness among other Member States, ANSES began setting up a European network on this topic. On 12 June 2014, ANSES held a kick-off meeting in Maisons-Alfort for this nutrivigilance information exchange network, which was attended by 13 Member States. Since then, a monthly exchange of information has led to the pooling of cases, literature and concerns. In 2015, this network expanded outside Europe with the inclusion of Brazil. In 2016, 19 countries were involved in the nutrivigilance network: Germany, Belgium, Brazil, Croatia, Cyprus, Denmark, Spain, Finland, France, Ireland, Italy, Latvia, Luxembourg, Norway, Netherlands, Slovenia, Sweden, Czech Republic and the United Kingdom. 3.2 Training activities organised As part of efforts to promote nutrivigilance among healthcare professionals, in 2016 ANSES continued its training actions among students of pharmacy (3 rd and 4 th years, Master and DU degree), medicine (3 rd year and Master) and sport science (Master and DU) at different faculties in France. It also offered training to other students in the framework of Master or specialised DU courses in nutrition. 3.3 Other actions A presentation of the nutrivigilance scheme was given to the members of Synadiet (the French Food Supplements Association). page 18 / 19 March 2017
19 4 Conclusions Since its creation in 2009, the nutrivigilance scheme has received a growing number of spontaneous reports. Nevertheless, 2016 saw an overall decline in the number of reported cases. These reports help improve consumer safety, because their analysis helps ANSES establish its priorities in terms of expert appraisals, in conjunction with its experts, and generate input for the risk assessments it carries out. In this regard, the Agency wishes to remind healthcare professionals of the importance of their participation as reporters to notify ANSES of cases of adverse effects that they suspect of being associated with the consumption of food supplements. ANSES asks them to continue questioning their patients during medical consultations about their use of food supplements and other special dietary foods such as fortified beverages, and to notify the nutrivigilance scheme of any adverse effects they are made aware of. ANSES reiterates that deficiencies in nutrients are very rare in the general population, and mainly concern a few specific substances (vitamin D, etc.) or particular population groups (pregnant women, the elderly, economically vulnerable populations, etc.). In these specific population groups, additional intakes of vitamins, minerals and other nutrients through food supplements may be of benefit, but on medical advice. For a large majority of the population, a balanced diet provides most of the nutrients required to meet nutritional needs. ANSES wishes to stress that food supplements are not without danger. They should not be used as a substitute for a varied diet, and the advice of a healthcare professional should always be sought when taking them. Pregnant and breastfeeding women, children and people taking medication should seek advice from their general practitioner before consuming food supplements. In general, the Agency advises consumers to: - report to a healthcare professional any adverse effect occurring after consumption of a food supplement; - comply with the conditions of use determined by the manufacturer; - avoid taking food supplements on a prolonged, repeated or multiple basis throughout the year without having sought the advice of a healthcare professional; - exercise extreme caution with products promoted as "miracle" cures and/or those sold through alternative channels, in particular through the Internet. page 19 / 19 March 2017
EFSA s Concise European food consumption database. Davide Arcella Data Collection and Exposure Unit
EFSA s Concise European food consumption database Davide Arcella Data Collection and Exposure Unit 1 The EFSA raison d être Risk assessment authority created in 2002 as part of a comprehensive program
More informationManuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal
Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal Public Health Public health is the science and art of preventing disease, prolonging
More informationFactsheet Energy Shots and Energy Drinks
Factsheet Energy Shots and Energy Drinks 1 Situation Energy drinks vs. energy shots Energy shots are energy drinks in concentrated form. A Red Bull Energy Shot (60 ml) contains the same "functional ingredients"
More informationMonthly measles and rubella monitoring report
SURVEILLANCE REPORT Monthly measles and rubella monitoring report December 2018 Period covered: 1 November 2017 to 31 October 2018 Introduction This monitoring report is based on measles and rubella data
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 22.12.2008 COM(2008) 882 final REPORT FROM THE COMMISSION TO THE COUNCIL, THE EUROPEAN PARLIAMENT, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE
More informationWCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
More informationWCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
More informationWCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION STAFF WORKING DOCUMENT
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 10.7.2008 SEC(2008) 2296 COMMISSION STAFF WORKING DOCUMENT CURRENT POSITION IN EU MEMBER STATES ON FOODS FOR PERSONS SUFFERING FROM CARBOHYDRATE METABOLISM
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL
EN EN EN COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 27.6.2008 COM(2008) 393 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL ON THE IMPLEMENTATION OF ARTICLE 9 OF COUNCIL
More informationLEBANON. WCPT COUNTRY PROFILE December 2018
LEBANON WCPT COUNTRY PROFILE December 2018 LEBANON NUMBERS 1600 1400 1200 1000 800 600 400 200 0 Physical therapists in the country Members in MO 1,480 1,480 Total PTs in country 800000 700000 600000 500000
More informationCNAPA Meeting Luxembourg September 2016
CNAPA Meeting Luxembourg September 2016 Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal RARHA Events Policy Dialogue and Final Conference
More informationDENMARK. WCPT COUNTRY PROFILE December 2018
DENMARK WCPT COUNTRY PROFILE December 2018 DENMARK NUMBERS 14000 12000 10000 8000 6000 4000 2000 0 Physical therapists in the country Members in MO 11,720 12,975 Total PTs in country 800000 700000 600000
More informationSummary of the risk management plan (RMP) for Duloxetine Mylan (duloxetine)
EMA/281284/2015 Summary of the risk management plan (RMP) for Duloxetine Mylan (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Mylan, which details the measures to be taken
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More informationOverview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
More informationOverview of European Consumption Databases
FEDERAL INSTITUTE FOR RISK ASSESSMENT Overview of European Consumption Databases Katrin Büsch Workshop Food Consumption Data and Dietary Exposure in the European Union, 15-16 May 2008, Berlin Introduction
More informationGERMANY. WCPT COUNTRY PROFILE December 2018
GERMANY WCPT COUNTRY PROFILE December 2018 GERMANY NUMBERS 160000 140000 120000 100000 80000 60000 40000 20000 0 Physical therapists in the country Members in MO 21,502 136,000 Total PTs in country 800000
More informationREPORT ON LAWS AND RECOMMENDATIONS ON DENTAL MERCURY MANAGEMENT IN THE EU
0 REPORT ON LAWS AND RECOMMENDATIONS ON DENTAL MERCURY MANAGEMENT IN THE EU 31/01/2018 0 1 Contents 1. Introduction... 2 2. Phasing out the use of dental amalgam... 3 3. Use of encapsulated dental amalgam...
More informationNutrient profiles for foods bearing claims
Nutrient profiles for foods bearing claims Fields marked with * are mandatory. Background Regulation (EC) 1924/2006 (Nutrition and Health Claims NHC Regulation) establishes EU rules on nutrition and health
More informationSummary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine)
EMA/450483/2015 Summary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Zentiva, which details the measures to be
More informationThe Risk of Alcohol in Europe. Bridging the Gap June 2004
The Risk of Alcohol in Europe Bridging the Gap 16-19 June 2004 1. What is the relationship between alcohol and the risk of heart disease? 2. What is the relationship between alcohol and the risk of other
More informationMeeting report, September 2005
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 24 October 2005 Doc. Ref. EMEA//322553/2005 COMMITTEE ON HERBAL MEDICINAL PRODUCTS () Meeting report, 19-20 September
More informationReal Life, Real PD Survey
Real Life, Real PD Survey Final Pan-European Survey Results Survey Objectives The survey was carried out to provide insights into the realities of living with PD and to highlight some of the symptoms of
More informationEuropean food consumption data: achievements made so far and future challenges. Davide Arcella Dietary and Chemical Monitoring (DCM) Unit
European food consumption data: achievements made so far and future challenges Davide Arcella Dietary and Chemical Monitoring (DCM) Unit Outline of the presentation Past EFSA activities in the food consumption
More informationREPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
EUROPEAN COMMISSION Brussels, 17.6.011 COM(011) 35 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
More informationThe Identification of Food Safety Priorities using the Delphi Technique
The Identification of Food Safety Priorities using the Delphi Technique Gene Rowe & Fergus Bolger, GRE 58th Advisory Forum Meeting, Luxembourg, 8-9 December 2015 EU RISK ASSESSMENT AGENDA (RAA) where priorities
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Calcium Sandoz 500 mg, effervescent tablets Calcium Sandoz 1000 mg, effervescent tablets Calcium Read all of this leaflet carefully because it contains important
More informationAn Overview on the Global Market of Dietary Supplements
An Overview on the Global Market of Dietary Supplements Abbas Kebriaeezadeh 1 and Alireza Yektadoost 2 Department of Pharmacoeconomics & Pharmaceutical Administration Faculty of Pharmacy, Tehran University
More informationMeasles and rubella monitoring January 2015
Measles and rubella monitoring January 215 Reporting on January December 214 surveillance data and epidemic intelligence data to the end of January 215 Main developments Measles During the 12-month period
More informationWhat s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey
What s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey Liisa Valsta Data Collection and Exposure Unit What s s on the menu in Europe? Background Attempts
More informationYersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Yersiniosis Key facts In 2015, 26 countries reported 7 279 confirmed yersiniosis cases in the EU/EEA. The overall notification rate was 2.0 cases
More informationAlcohol in Europe and Brief Intervention. Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe
Alcohol in Europe and Brief Intervention Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe Global risk factors ranked by attributable burden of disease 2010 (GBD, Lancet,
More informationPharmacovigilance Methods and Post-Authorisation Safety Studies
Pharmacovigilance Methods and Post-Authorisation Safety Studies Alex Dodoo Director, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance Accra, Ghana Objectives At the end of this module
More informationSUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 10 DECEMBER 2012 (Section General Food Law)
EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL Brussels, SANCO E 1718316 SUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 10 DECEMBER 2012 (Section
More informationPACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Technescan MIBI 1 mg, kit for radiopharmaceutical preparation
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Technescan MIBI 1 mg, kit for radiopharmaceutical preparation [Tetrakis(2-methoxy-2-methylpropyl-1 isocyanide)copper(i)] tetrafluoroborate Read all of this
More informationEuropean status report on alcohol and health Leadership, awareness and commitment
European status report on alcohol and health 2014 Leadership, awareness and commitment Leadership, awareness and commitment Background Strong leadership from national and local governments is essential
More informationEuSalt Response to the Discussion Paper on the setting of. maximum and minimum amounts for. vitamins and minerals in foodstuffs
EuSalt Response to the Discussion Paper on the setting of maximum and minimum amounts for vitamins and minerals in foodstuffs EuSalt aisbl avenue de l'yser 4 B-1040 Brussels Phone +32 (0)2 737.10.90 Fax
More informationEUROPEAN GUIDE ON QUALITY IMPROVEMENT IN COMPREHENSIVE CANCER CONTROL
EUROPEAN GUIDE ON QUALITY IMPROVEMENT IN COMPREHENSIVE CANCER CONTROL Policy Paper on National Cancer Control Programmes (NCCPs)/ Cancer Documents in Europe Marjetka Jelenc, Tit Albreht, Karen Budewig,
More informationFoodstuffs - Determination of vitamin D by high performance liquid chromatography - Measurement of cholecalciferol (D3) or ergocalciferol (D2)
Irish Standard Foodstuffs - Determination of vitamin D by high performance liquid chromatography - Measurement of cholecalciferol (D3) or ergocalciferol (D2) NSAI 2009 No copying without NSAI permission
More informationProject Meeting Prague
Project Meeting Prague IO1 Assessment 9.11.217 CHRISTINA PADBERG ON BEHALF OF FRANKFURT UAS Current Status Assessment matrix was fully evaluated Experts have been interviewed, Interviews were fully evaluated
More informationTiorfan Hidrasec Tiorfix Tiorfast 100 mg PACKAGE LEAFLET
Tiorfix Tiorfast 100 mg PACKAGE LEAFLET 1 Tiorfix Tiorfast 100 mg Package leaflet: Information for the user 100 mg hard capsules Racecadotril Read all of this leaflet carefully before you start taking
More informationOpinion of the Scientific Committee on Food on an application from ADM for approval of plant sterol-enriched foods
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Scientific Opinions C2 - Management of scientific committees; scientific co-operation and networks Scientific Committee
More informationMarket surveillance of medical devices
Market surveillance of medical devices A joint action on market surveillance of medical devices to reinforce public health protection Information for healthcare professionals Introduction The European
More informationDepartment of Biological Standardisation OMCL Network & Healthcare (DBO)
Department of Biological Standardisation OMCL Network & Healthcare (DBO) Implementation of Pathogen Reduction Technologies for Blood Components for Transfusion: Updated Table 2009-2010 COUNCIL OF EUROPE
More informationPress kit 12 july 2017
#INCA3 Press kit 12 july 2017 Third study on the food consumption and eating habits of the French population Changes in consumption habits and patterns, new issues in the areas of food safety and nutrition
More informationThis document is a preview generated by EVS
EESTI STANDARD EVS-EN 14663:2006 Foodstuffs - Determination of vitamin B6 (including its glycosylated forms) by HPLC Foodstuffs - Determination of vitamin B6 (including its glycosylated forms) by HPLC
More informationPerspectives from regions: successes and challenges in promoting seasonal influenza vaccine usage in the EU
Perspectives from regions: successes and challenges in promoting seasonal influenza vaccine usage in the EU N. Safrany European Commission Pr. A. Nicoll ECDC 2 nd WHO GAP mtg 12-14 July 2011 Background
More informationEFSA s activities on data collection (Art. 33) and proposal for a new initiative (EUMENU) H. Deluyker Director
EFSA s activities on data collection (Art. 33) and proposal for a new initiative (EUMENU) H. Deluyker Director Scientific Cooperation and Assistance 43 rd Management Board Meeting Stockholm, 17 December
More informationSummary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin)
EMA/247834/2014 Summary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin) Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised
More informationPharmacy Ownership and Establishment
Pielikums Nr.2 Pharmacy Ownership and Establishment Ref: 09.07.06E 012FS Pharmacy Ownership and Establishment Ownership information on who is entitled to own a Pharmacy. Reference should be made if ownership
More informationWhere do EU Contries set the limit for low risk drinking.
Where do EU Contries set the limit for low risk drinking. Results from the EU RARHA survey E. Scafato,L. Galluzzo, S. Ghirini, C. Gandin Istituto Superiore di Sanità, Italy WP5: Outline of the work (tasks)
More informationEuropean Collaboration on Dementia. Luxembourg, 13 December 2006
European Collaboration on Dementia Luxembourg, 13 December 2006 2005 Call for projects Special attention has also to be given to information and definition of indicators on neurodegenerative, neurodevelopment,
More informationEuropean Status report on Alcohol and Health
European Status report on Alcohol and Health Dr Lars Moller Regional Advisor a.i. WHO Regional Office for Europe Main killers in the WHO European Region Source: Preventing chronic diseases. A vital investment.
More informationthe high CVD risk smoker
Smoking Cessation: population and patients A comprehensive approach to the smoker the high CVD risk smoker Catriona Jennings Cardiovascular Specialist Research Nurse Imperial College London European Society
More informationTo provide information on the new standard, a number of EOG members formed a committee to compile information on the following basis:
EN 13537 Sleeping Bag Standard Information for Retailers 30.12.2004 Disclaimer This information sheet has been provided by the EOG to help companies assess the implications of the new EN 13537 norm on
More informationFood Legislation. Janet Worrell July 2014
Food Legislation Janet Worrell July 2014 Topics to be covered Food legislation what is a supplement origin of food legislation Making a product from a concept claim development Regulation in transition
More informationThe Director General Maisons-Alfort, 30 July 2018 OPINION. of the French Agency for Food, Environmental and Occupational Health & Safety
The Director General Maisons-Alfort, 30 July 2018 OPINION of the French Agency for Food, Environmental and Occupational Health & Safety on the development of chronic TRVs for the oral and respiratory routes
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin
PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need
More informationL 322/24 Official Journal of the European Union
L 322/24 Official Journal of the European Union 22.11.2006 COMMISSION RECOMMENDATION of 16 November 2006 on the monitoring of background levels of dioxins, dioxin-like PCBs and non-dioxin-like PCBs in
More informationUK bowel cancer care outcomes: A comparison with Europe
UK bowel cancer care outcomes: A comparison with Europe What is bowel cancer? Bowel cancer, which is also known as colorectal or colon cancer, is a cancer that affects either the colon or the rectum. The
More informationA report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%
% of reported measles cases WHO EpiBrief A report on the epidemiology of selected vaccine-preventable diseases in the European Region No. /17 This issue of WHO EpiBrief provides an overview of selected
More informationREVIEW OF THE ANALYSIS RELATED TO RABIES DIAGNOSIS AND FOLLOW-UP OF ORAL VACCINATION PERFORMED IN NRLS IN 2015
European Union European Union WHO Collaborating OIE Reference Reference Centre Reference NANCY LABORATORY FOR RABIES AND WILDLIFE Laboratory for Rabies Institute for Rabies Serology for Research and Management
More informationThis document is a preview generated by EVS
EESTI STANDARD EVS-EN 1640:2004 Stomatoloogia. Meditsiinivahendid stomatoloogias. Aparatuur Dentistry - Medical devices for dentistry - Equipment EESTI STANDARDIKESKUS EESTI STANDARDI EESSÕNA NATIONAL
More informationSTANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH SECTION ON GENERAL FOOD LAW Summary Record of Meeting of 25 June 2007
STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH SECTION ON GENERAL FOOD LAW Summary Record of Meeting of 25 June 2007 Chairman: Mr Basil Mathioudakis (except points 1 and 7) 1. Consultation paper
More informationLouisville '19 Attachment #69
Telephone Meeting Approved and why I propose Using zoom to fulfill both Phone and Virtual video meeting Formats. The first established phone meeting Sanctioned by Gamblers Anonymous (listed on Trustee
More informationThis document is a preview generated by EVS
TECHNICAL REPORT RAPPORT TECHNIQUE TECHNISCHER BERICHT CEN/TR 17223 March 2018 ICS 03.100.70; 11.040.01 English version Guidance on the relationship between EN ISO 13485: 2016 (Medical devices - Quality
More informationImpARAS. Improving Allergy Risk Assessment Strategy for new food proteins. Kitty Verhoeckx, Scientist, TNO, The Netherlands
ImpARAS Improving Allergy Risk Assessment Strategy for new food proteins Kitty Verhoeckx, Scientist, TNO, The Netherlands COST Action European network of scientists and researchers and is open to researchers
More informationCross Border Genetic Testing for Rare Diseases
Cross Border Genetic Testing for Rare Diseases EUCERD Joint Action WP8 Helena Kääriäinen National Institute for Health an Welfare, Helsinki, Finland Starting point Possibilities and demand for genetic
More informationTable 7.1 Summary information for lung cancer in Ireland,
7 Lung cancer 7.1 Summary Lung cancer is the third most common cancer in Ireland, accounting for 15% of cancers in men and 9% in women, if non-melanoma skin cancer is excluded (table 7.1). Each year, approximately
More informationRheumatoid Arthritis Disease Burden and Access to Treatment
Berlin, April 2012 Rheumatoid Arthritis Disease Burden and Access to Treatment Gisela Kobelt, PhD Visiting Professor, Lund University (Sweden) President, European Health Economics (France) Disclaimers
More informationUnderage drinking in Europe
Underage drinking in Europe There are two major studies on underage drinking which are published every 4 years: HBSC (Health Behaviour in School-aged Children) and ESPAD (The European School survey Project
More informationTable 6.1 Summary information for colorectal cancer in Ireland,
6 Colorectal cancer 6.1 Summary Colorectal cancer is the second most common cancer in Ireland (excluding non-melanoma skin cancer). It accounts for 12% of all malignant neoplasia in females and 15% in
More informationAlcohol-related harm in Europe and the WHO policy response
Alcohol-related harm in Europe and the WHO policy response Lars Moller Programme Manager World Health Organization Regional Office for Europe Date of presentation NCD global monitoring framework: alcohol-related
More informationOfficial Journal of the European Union REGULATIONS
L 259/2 REGULATIONS COMMISSION DELEGATED REGULATION (EU) 2017/1798 of 2 June 2017 supplementing Regulation (EU) No 609/2013 of the European Parliament and of the Council as regards the specific compositional
More informationTrichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods
Annual Epidemiological Report for 2015 Trichinellosis Key facts In 2015, a total of 156 confirmed cases of trichinellosis was reported from 29 EU/EEA countries. The overall notification rate was 0.03 cases
More informationInequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe
Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe 21st Congress of the European Association of Dental Public Health 1 October 2016 Budapest
More informationJOSEFIEN VENDRIK, QUALITY MANAGER IRENE JONGENELEN, COÖRDINATOR CLINICAL SUPPLIES MANAGEMENT/ SENIOR CLINICAL STUDY MANAGER
Food for Thought JOSEFIEN VENDRIK, QUALITY MANAGER IRENE JONGENELEN, COÖRDINATOR CLINICAL SUPPLIES MANAGEMENT/ SENIOR CLINICAL STUDY MANAGER CLINOPS DAG, 12 APRIL 2018 HISTORY OF RESEARCH AND DEVELOPMENT
More informationEuropean monthly measles monitoring (EMMO)
SURVEILLANCE REPORT European monthly measles monitoring (EMMO) Issue 9: 19 March 2012 Main developments In January 2012, 584 cases of measles were reported by the 29 contributing EU and EEA countries.
More informationPalliative nursing care of children and young people across Europe
Palliative nursing care of children and young people across Europe Results of a postal survey in August 2016 Updated in April 2017 (presented at the 29th PNAE-meeting in Naples/Italy on 28th April 2017)
More informationLaura Beatriz Herrero Montarelo, Maria Dolores Gómez Vázquez and Victorio José Teruel Muñoz
Collaboration Laura Beatriz Herrero Montarelo, Maria Dolores Gómez Vázquez and Victorio José Teruel Muñoz Nutritional Risk Management Area of the Subdirectorate-General for Food Safety Promotion Spanish
More informationLow risk drinking guidelines in Europe: results from RARHA survey E. Scafato, Istituto Superiore di Sanità, Italy
Low risk drinking guidelines in Europe: results from RARHA survey E. Scafato, Istituto Superiore di Sanità, Italy Work Package Guidelines Co-led by the National Institute for Health and Welfare, Finland,
More informationMedia Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences
Media Release Embargoed 00.01 CET Monday 12 th March 2012 Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences Up to 70 percent of
More informationCurrent dietary habits in Europe far from plant based eating
Current dietary habits in Europe far from plant based eating Stefaan De Henauw Ghent University Department of Public Health Stefaan.dehenauw@ugent.be The menu What is plant based diet? Nutrition transition
More informationStatement on the safety of D-ribose
STATEMENT ADOPTED: 24 October 2018 doi: 10.2903/j.efsa.2018.5485 Statement on the safety of D-ribose EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Jacqueline Castenmiller,
More information(Adopted by the Committee of Ministers on 19 January 2011 at the 1103rd meeting of the Ministers Deputies)
Resolution CM/ResAP(2011)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients (Adopted by the Committee of Ministers on 19 January
More informationSummary of the risk management plan (RMP) for Duloxetine Lilly (duloxetine)
EMA/674705/2014 Summary of the risk management plan (RMP) for Duloxetine Lilly (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Lilly which details the measures to be taken
More informationAlcohol Prevention Day
Alcohol Prevention Day Rome, 16 May 2018 Hana Horka Policy Officer, Unit C4 Health Determinants and International Relations European Commission DG Health and Food Safety (SANTE) Alcohol consumption in
More informationHealth and. Consumers
www.openprogram.eu EU action on obesity Obesity Prevention through European Network Closing event Amsterdam 25 November 2016 Attila Balogh Health determinants and inequalities European Commission Directorate-General
More informationSummary of the risk management plan (RMP) for Pregabalin Mylan (pregabalin)
EMA/285074/2015 Summary of the risk management plan (RMP) for Pregabalin Mylan (pregabalin) This is a summary of the risk management plan (RMP) for Pregabalin Mylan, which details the measures to be taken
More informationTable Of Content. The European Influenza Surveillance Scheme... 2 Summary... 3 Coordinator, Leader contact and partners Outputs...
Table Of Content The European Influenza Surveillance Scheme... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Institut Pasteur... 6 Health Division... 6 Nphs Communicable Disease Surveillance
More informationGood Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014
Good Laboratory Practice EU-Serbia screening meeting Brussels, 19 June 2014 Table of contents 1. Background information on the principles of GLP 2. EU legal basis for GLP 3. Role of Member States 4. Role
More informationPreliminary library of alcohol health information and warning labels
Preliminary library of alcohol health information and warning labels Introduction Although labelling is a means to deliver a clear message to the consumer, as a standalone measure, and in the absence of
More information